$FRMI

Today’s top U.S. stock movers: Fermi, NIQ and others surge on AI and biotech catalysts

Investing.com reports major U.S. stock movers, led by FRMI up 22.2% on an AI campus lease and potential revenue expansion, ALMR up 28.3% after launching an immune profiling panel, and Hertz up 24.5% on index removal and heavy options activity. Other gainers include Septerna, Rapid7, Kopin, and NextNav, with catalysts tied to AI, biotech, and earnings.

Original reporting
Published Aug 11, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 6:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$FRMI
Bullish
low confidence
Mentioned
$FRMI · $ALMR · $KOPN · $RPD · $NN · $COMP
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FRMIBullishLow
01

Why it matters

The only actionable edge is identifying which tickers are tied to same-day company-specific catalysts versus flow-driven moves; however, the scrape lacks verification details for several claims.

02

Market read

This is a catalyst-driven mover list rather than a single-company fundamental update; it is most useful for short-term momentum and volatility management.

03

What to watch

The scrape does not provide primary sources (filings, contract terms, trial endpoints, or guidance numbers) for several catalysts, so traders should verify before sizing.

Relevance 4/10Novelty 3/10Timing: today’s intraday U.S. stock-mover snapshot

Background

The article is a daily U.S. market wrap focused on top gainers, attributing moves to AI, energy, biotech catalysts, and some speculation-driven trading.

Company-level read

Ticker impact

$FRMIBullishLow confidence
Context

FRMI is cited as up 22.2% on an alleged $6.5B AI campus lease that could expand contracted revenue.

Expected impact

Near-term upside bias with elevated volatility; follow-through depends on lease confirmation and expansion terms.

Evidence & confidence

The article attributes the move to a large AI lease and frames potential revenue expansion, but provides no primary filing, contract terms, or verification.

$ALMRBullishMedium confidence
Context

ALMR is listed as up 28.3% after launching a new immune profiling panel expanding its biotech offering.

Expected impact

Likely continued strength if investors treat the panel as incremental revenue and adoption accelerates.

Evidence & confidence

The text links the gain to a specific product launch, which is a concrete company-specific catalyst even without financial figures.

$KOPNNeutralLow confidence
Context

Kopin (KOPN) is up 21.1% and the article says insider activity is reported, fueling speculative action.

Expected impact

Short-term volatility likely persists; conviction depends on the nature and size of the insider transaction.

Evidence & confidence

The scrape mentions insider activity but does not specify transaction type, size, or filing source, limiting signal quality.

$RPDNeutralMedium confidence
Context

Rapid7 (RPD) is up 18.7% after an earnings beat with a neutral outlook mentioned in the article.

Expected impact

Moderate upside bias initially, with risk of pullback if investors focus on the neutral outlook.

Evidence & confidence

The text provides a clear earnings-beat catalyst and notes outlook neutrality, which is actionable for near-term positioning.

$NNNeutralLow confidence
Context

NextNav (NN) is up 16.7% and the article attributes the move to location-tech news with modest guidance.

Expected impact

Choppy trading; upside continuation possible but likely capped without stronger guidance.

Evidence & confidence

The scrape does not provide the specific guidance numbers or the exact news item beyond broad framing.

$COMPNeutralLow confidence
Context

Compass Diversified (COMP) is up 12.4% and the article frames it as a dividend play and value rebound.

Expected impact

Limited upside unless there is a fresh capital return or earnings catalyst not included in the scrape.

Evidence & confidence

The catalyst is narrative-based (dividend play, value rebound) with no concrete new corporate action described.

Market effects

AI and biotech names are highlighted as leading movers, reinforcing a near-term risk-on rotation into catalyst-driven small and mid caps.

Primarily U.S.-centric flow story; no direct cross-market transmission details provided beyond general volatility.

No explicit global macro or international policy linkage beyond a brief mention of Hormuz reopening jitters.

Counterpoint

Some of the biggest movers appear driven by positioning (index removal, options activity) or vague “insider activity” rather than verifiable fundamentals, increasing mean-reversion risk.

Key entities

  • Fermi Inc.

    Named as the top mover, up 22.2% on an alleged $6.5B AI campus lease and potential revenue expansion.

  • ALMR

    Named as a biotech product-launch winner, up 28.3% on a new immune profiling panel.

  • Hertz Global Holdings, Inc.

    Named as a high-volatility mover, up 24.5% on index removal and options activity.

  • Rapid7 Inc

    Named as an earnings-beat winner, up 18.7% with neutral outlook mentioned.

Related articles

$ALMRMed

Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68%

Alamar Biosciences Inc (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with consumables revenue representing 53% of total revenue. Gross margin reached 61.5%. Full-year guidance was raised to $121-123M. Net loss widened to $13.3M. The company secured partnerships with UK Biobank and GSK. Q4 revenue guidance implies flat sequential growth, raising concerns about near-term momentum.

$ALMRMed

Alamar Biosciences Q3 Earnings Call Highlights

Alamar Biosciences (ALMR) reported Q3 earnings, with revenue up 64% YoY. Key projects include UK Biobank work and a GSK partnership. Biopharma customers now represent 49% of revenue. Gross profit rose to $20.6M, but operating loss widened to $15.1M. The company raised its 2026 revenue guidance to $121M-$123M. ALMR plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027.

Med

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

$ALMRMed

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o